A developmental approach to drug-induced liver injury in newborns and children

Area of Science:

• Pharmacology
• Hepatology
• Neonatal Medicine

Background:

• The liver is the primary site of drug metabolism.
• Neonatal liver metabolic activity undergoes significant developmental changes, influencing drug sensitivity.
• Fetal and newborn livers have reduced capacity for drug metabolism, detoxification, and excretion compared to adults.

Purpose of the Study:

• To review acute and chronic liver toxicity from common neonatal drugs.
• To detail the biochemical profile of fetal and neonatal liver drug metabolism.
• To examine toxic metabolites and histological liver damage from therapeutic drug use in neonates.

Main Methods:

• Review of literature on neonatal drug metabolism and liver toxicity.
• Analysis of biochemical differences in fetal and neonatal liver enzyme activity (e.g., cytochrome P450).
• Examination of toxic metabolite formation and cellular death mechanisms in drug-induced hepatitis.

Main Results:

• Lower cytochrome P450 content in fetal livers (30-60% of adult values) contributes to prolonged drug action and reduced toxicity.
• Reduced Phase I enzyme activity may lower adverse drug effects in newborns.
• Newborns exhibit enhanced glutathione synthesis for toxic metabolite inactivation.

Conclusions:

• Neonatal liver immaturity influences drug pharmacokinetics and toxicity profiles.
• Understanding developmental liver biochemistry is key to optimizing neonatal pharmacotherapy.
• Drug-induced liver injury in neonates requires careful consideration of metabolic pathways and cell death mechanisms.